First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors

被引：0
|
作者：
Sandhu, S. K. [1 ,2 ,3 ,4 ,5 ,6 ]
Fong, P. C. [1 ,2 ,3 ,4 ,5 ,6 ]
Frentzas, S. [1 ,2 ,3 ,4 ,5 ,6 ]
Patnaik, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Papadopoulos, K. [1 ,2 ,3 ,4 ,5 ,6 ]
Tromp, B. [1 ,2 ,3 ,4 ,5 ,6 ]
Puchalski, T. [1 ,2 ,3 ,4 ,5 ,6 ]
Berns, B. [1 ,2 ,3 ,4 ,5 ,6 ]
Tolcher, A. W. [1 ,2 ,3 ,4 ,5 ,6 ]
De-Bono, J. S. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] START, San Antonio, TX USA
[3] Ortho Biotech, Oncol, London, England
[4] Ortho Biotech, Oncol, Res & Dev, London, England
[5] S Texas Accelerated Res Therapeut, San Antonio, TX USA
[6] Inst Canc Res, London SW3 6JB, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13500
引用
收藏
页数：1
相关论文
共 50 条
  • [31] FIRST-IN-HUMAN PHASE 1/2 STUDY OF THE FIRST-IN-CLASS SUMO-ACTIVATING ENZYME INHIBITOR TAK-981 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS OR RELAPSED/REFRACTORY LYMPHOMA: PHASE 1 RESULTS
    Dudek, Arkadiusz
    Juric, Dejan
    Dowlati, Afshin
    Vaishampayan, Ulka
    Assad, Hadeel
    Rodon, Jordi
    Chao, Bo
    Wang, Bingxia
    Gibbs, John
    Shinde, Vaishali
    Friedlander, Sharon
    Berger, Allison
    Ward, Christine
    Martinez, Alonzo
    Gharavi, Robert
    Gomez-Pinillos, Alejandro
    Proscurshim, Igor
    Olszanski, Anthony
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A505 - A506
  • [32] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [33] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elena Elez
    Carlos Gomez-Roca
    Arturo Soto Matos-Pita
    Guillem Argiles
    Thibaud Valentin
    Cinthya Coronado
    Jorge Iglesias
    Teresa Macarulla
    Sarah Betrian
    Salvador Fudio
    Katrin Zaragoza
    Josep Tabernero
    Jean-Pierre Delord
    Investigational New Drugs, 2019, 37 : 674 - 683
  • [34] A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
    Tabernero, Josep
    Dirix, Luc
    Schoffski, Patrick
    Cervantes, Andres
    Antonio Lopez-Martin, Jose
    Capdevila, Jaume
    van Beijsterveldt, Ludy
    Platero, Suso
    Hall, Brett
    Yuan, Zhilong
    Knoblauch, Roland
    Zhuang, Sen Hong
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6313 - 6321
  • [35] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [36] A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid Tumors
    Dowlati, Afshin
    Vlahovic, Gordana
    Natale, Ronald B.
    Rasmussen, Erik
    Singh, Indrajeet
    Hwang, Yuying C.
    Rossi, John
    Bass, Michael B.
    Friberg, Gregory
    Pickett, Cheryl A.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4574 - 4584
  • [37] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
    Naing, Aung
    Gelderblom, Hans
    Gainor, Justin F.
    Forde, Patrick M.
    Butler, Marcus
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Schellens, Jan H. M.
    Soria, Jean-Charles
    Taylor, Matthew H.
    Silva, Antonio P.
    Li, Zhonggai
    Bilic, Sanela
    Cameron, Scott
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.
    Patnaik, Amita
    Morgensztern, Daniel
    Mantia, Charlene
    Tannir, Nizar M.
    Harshman, Lauren C.
    Hill, Jonathan
    White, Kerry
    Chung, Jou-Ku
    Bowers, Beth
    Sciaranghella, Gaia
    Lee, Benjamin
    Choueiri, Toni K.
    Smith, Lon S.
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
    Razak, Albiruni R. A.
    Soerensen, Morten Mau
    Mahipal, Amit
    Shacham, Sharon
    Yau, Cindy Y. F.
    Lassen, Ulrik Niels
    McCauley, Dilara
    Cooksey, Jennifer
    Tan, David Shao Peng
    Saint-Martin, Jean-Richard
    Landesman, Yossi
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumors
    Mau-Soerensen, Morten
    Razak, Albiruni R. A.
    Shields, Anthony Frank
    Gabrall, Nashat Y.
    Gereeltano, John F.
    Shacham, Sharon
    Lassen, Ulrlk Niels
    Rashal, Taml
    Cooksoy, Jennifer
    Landosman, Yosof
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Bedard, Philippe L.
    Mahaseth, Hemchandra
    Mlrza, Mansoor Raza
    Mahipal, Arnit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345